LILACS – Literatura Latinoamericana y del Caribe de Ciencias de la Salud

Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report

Ospina, Fabio E; Echeverri, Alex; Posso-Osorio, Iván; Jaimes, Lina; Gutierrez, Jaiber; Tobón, Gabriel J.

Colomb. med; 48 (2), 2017

Abstract Case description: Five-year-old female patient with hereditary hemorrhagic telangiectasia. Clinical Findings: Deterioration of cardiopulmonary function with higher oxygen requirements secondary to pulmonary arteriovenous shunts, epistaxis. Treatment and Outcome: The patient was treated with...

Inhibidores de la Angiogénesis/uso terapéutico, Bevacizumab/uso terapéutico, Telangiectasia Hemorrágica Hereditaria/tratamiento farmacológico, Inhibidores de la Angiogénesis/farmacología, Bevacizumab/farmacología, Telangiectasia Hemorrágica Hereditaria/fisiopatología, Resultado del Tratamiento, Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores

Fulltext

Critical evaluation of the off-label indication and of the risks associated to the use of multi-dose vials on the treatment of age-related macular degeneration

Age-related macular degeneration (AMD) is an ocular inflammatory diseases treated mainly by means of a bevacizumab (Avastin®) or ranibizumab (Lucentis®) intravitreal injection. Among these drugs, only ranibizumab has a specific therapeutic indication for AMD. Considering that, the off-label use on opht...